NCT04040907View on ClinicalTrials.gov

The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 13, 2019

Primary Completion Date

January 20, 2021

Study Completion Date

May 30, 2021

Conditions
Gout
Interventions
DRUG

XNW3009

XNW3009 is a small molecule hURAT1 inhibitor

DRUG

Placebo

Placebo and active drug will have the same appearance

Trial Locations (1)

6009

Linear Clinical Research, Perth

Sponsors
All Listed Sponsors
lead

Evopoint Biosciences Inc.

INDUSTRY